Ubs Group Ag Enlivex Therapeutics Ltd. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ENLV
# of Institutions
24Shares Held
2.58MCall Options Held
20.8KPut Options Held
3K-
Armistice Capital, LLC New York, NY2.14MShares$2.44 Million0.06% of portfolio
-
Morgan Stanley New York, NY246KShares$280,1590.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny74.8KShares$85,2590.0% of portfolio
-
Sigma Investment Counselors Inc30KShares$34,2000.0% of portfolio
-
Xtx Topco LTD London, X022.7KShares$25,8310.0% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $21M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...